The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high risk patients with complete remission of diffuse large B lymphoma / stage III follicular lymphoma after chemotherapy in the initial R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus the monoclonal antibody rituximab) regimen
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
250
Ruijin Hospital
Shanghai, China
RECRUITINGOverall Survival
Time frame: From date of randomization until the date of trail closed or date of death from any cause, whichever came first, up to 100 months
Progress Free Survival
Time frame: From date of randomization until the date of trail closed or disease progressed, whichever came first, up to 100 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.